Technology Description
The OncoGS-FFPE test utilizes NGS technology with molecular barcoding, allowing the analysis of tumor DNA from FFPE samples to examine multiple genes simultaneously. It aids in identifying appropriate targeted therapies for patients with lung, colorectal, breast, ovarian, gastric, thyroid, melanoma, prostate, cervical, pancreatic cancers, as well as GIST, Erdheim-Chester, Langerhans, and Rosai-Dorfman diseases.
OncoGS-FFPE focuses on detecting somatic mutations in 21 high- and moderate-penetrance genes, recommended by the National Comprehensive Cancer Network (NCCN) guidelines for screening somatic mutations. This is crucial for prescribing appropriate TKI therapies using Next-Generation Sequencing (NGS) technology.
Materials include in the kit
-
- Extracting DNA from FFPE
- Library preparation
- Hybridization and capture specific DNA fragments for analysis
- Clean up kit
- Instruction of use
- Training process to use the kit
